1-23I-MIBG Thyroid Uptake: Implications for MIBG Imaging of the Heart

Overview

Journal J Nucl Cardiol

Specialty Cardiology & Vascular Diseases

Date 2015 May 13

PMID 25963285

Citations 6

Authors

Raffaele Giubbini

Elisa Milan

Claudio Marcassa

Barbara Paghera

Federica Fracassi

Luca Camoni

Carlo Rodella

Francesco Bertagna

Federica Motta

Mattia Bertoli

Riccardo Campini

Affiliations

Soon will be listed here.

Abstract

Background: 123I-MIBG has been widely used in patients with heart failure and neurological disorders. The patients are pre-treated with Lugol's oral solution or potassium perchlorate to prevent thyroid uptake of unlabeled 123I to limit the thyroid radiation exposure. However, despite the inhibition of the iodide pump, the thyroid is frequently visualized. The aim of this study was to study the pattern of thyroid uptake.

Methods: We reviewed the 123I-MIBG images of 57 patients studied in three different centers in Italy for cardiac (n = 42) or neurological (n = 15) indications. They were imaged at 15 minutes and 4 hours after injection and in all patients, the thyroid was included in the imaging field of view. In 2 of the 3 centers, the patients were pre-treated with Lugol's oral solution and/or potassium perchlorate (group 1) but in the third center, they were not (group 2). The following imaging parameters were evaluated: heart-to-mediastinum ratio (H/M), thyroid-to-mediastinum ratio (T/M) at 4 hours, and tracer wash out from the heart (HWO) and from the thyroid (TWO).

Results: In the cardiac patients, the HWO was 22.98 ± 7.16% and TWO was 11.4 ± 11.86% (P < .0001). The TWO was 12.2 ± 13.1% in group 1 and 10.05 ± 8.97% in group 2 (P = NS). In the neurological patients the HWO was 26 ± 8.1% and the TWO was 20.32 ± 6.41 (P < .05). The difference in TWO was statistically significant (P < .01) between cardiac and neurological patients, whereas the HWO was not. The 4-hour H/M was 1.49 ± 0.23 in cardiac patients vs 1.4 ± 0.39 in neurological patients (P = NS). The 4-hour T/M was 1.33 ± 0.3 in cardiac patients vs 1.15 ± 0.13 in neurological patients (P < 0.05).

Conclusion: The thyroid visualization in MIBG imaging is likely an expression of thyroid sympathetic innervation. The differences in TWO and T/M ratio in cardiac and neurological patients probably express differences in thyroid dopaminergic receptors. Thus, pre-treatment with potassium perchlorate or Lugol's solution may not be justified in patients undergoing 123I-MIBG imaging in whom the risk of side effects due to pre-treatment could be higher than the risk due to thyroid radiation exposure.

Citing Articles

Thyroid [I]MIBG uptake in Parkinson's disease and diabetes mellitus.

Fedorova T, Knudsen K, Rasmussen T, Horsager J, Nahimi A, Skjaerbaek C IBRO Neurosci Rep. 2023; 14:342-345.

PMID: 37006721 PMC: 10063394. DOI: 10.1016/j.ibneur.2023.03.006.

Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD.

Miyamoto K, Saiki S, Matsumoto H, Suzuki A, Yamashita Y, Iseki T Ann Neurol. 2022; 93(2):303-316.

PMID: 36128871 PMC: 10092289. DOI: 10.1002/ana.26510.

Thyroid function after diagnostic I-metaiodobenzylguanidine in children with neuroblastic tumors.

Clement S, Tytgat G, van Trotsenburg A, Kremer L, van Santen H Ann Nucl Med. 2022; 36(6):579-585.

PMID: 35499668 PMC: 9132835. DOI: 10.1007/s12149-022-01743-7.

Misdiagnosis of Paraganglioma by I-mIBG Without Stable Iodine Blockade of Thyroidal Radioiodine Uptake.

Chen Cardenas S, Duan D, Rooper L, Santhanam P, Cooper D, Ladenson P J Endocr Soc. 2020; 4(9):bvaa099.

PMID: 32793847 PMC: 7414919. DOI: 10.1210/jendso/bvaa099.

Imaging Parkinson's disease below the neck.

Borghammer P, Knudsen K, Fedorova T, Brooks D NPJ Parkinsons Dis. 2017; 3:15.

PMID: 28649615 PMC: 5460119. DOI: 10.1038/s41531-017-0017-1.

References

Arora R, Ferrick K, Nakata T, Kaplan R, Rozengarten M, Latif F . I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003; 10(2):121-31. DOI: 10.1067/mnc.2003.2. View

Kasama S, Toyama T, Iwasaki T, Sumino H, Kumakura H, Minami K . Evaluation of cardiac sympathetic nerve activity and aldosterone suppression in patients with acute decompensated heart failure on treatment containing intravenous atrial natriuretic peptide. Eur J Nucl Med Mol Imaging. 2014; 41(9):1683-91. DOI: 10.1007/s00259-014-2754-2. View

Lebasnier A, Lamotte G, Manrique A, Peyronnet D, Bouvard G, Defer G . Potential diagnostic value of regional myocardial adrenergic imaging using (123)I-MIBG SPECT to identify patients with Lewy body diseases. Eur J Nucl Med Mol Imaging. 2015; 42(7):1043-51. DOI: 10.1007/s00259-015-2989-6. View

Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y . Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J. 2007; 28(8):989-95. DOI: 10.1093/eurheartj/ehm048. View

Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T . MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. Parkinsonism Relat Disord. 2013; 20(3):267-73. DOI: 10.1016/j.parkreldis.2013.11.001. View

Toyama T, Aihara Y, Iwasaki T, Hasegawa A, Suzuki T, Nagai R . Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med. 1999; 40(2):217-23. View

Tipre D, Goldstein D . Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med. 2005; 46(11):1775-81. View

Guidez D, Behnke S, Halmer R, Dillmann U, Fassbender K, Kirsch C . Is reduced myocardial sympathetic innervation associated with clinical symptoms of autonomic impairment in idiopathic Parkinson's disease?. J Neurol. 2013; 261(1):45-51. DOI: 10.1007/s00415-013-7135-4. View

Bogazzi F, Bartalena L, Tomisti L, DellUnto E, Cosci C, Sardella C . Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy. J Endocrinol Invest. 2008; 31(6):515-9. DOI: 10.1007/BF03346400. View

10.

Navarro-Otano J, Gaig C, Muxi A, Lomena F, Compta Y, Buongiorno M . 123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease. Parkinsonism Relat Disord. 2013; 20(2):192-7. DOI: 10.1016/j.parkreldis.2013.10.025. View

11.

Maruyama Y, Yamada T, Murakami K, Kumano R . Comparison of the diagnostic performance of H/M ratio between early and delayed phases for Lewy body disease. Nucl Med Commun. 2015; 36(5):477-80. PMC: 4482458. DOI: 10.1097/MNM.0000000000000271. View

12.

Nishioka S, Martinelli Filho M, Brandao S, Giorgi M, Vieira M, Costa R . Cardiac sympathetic activity pre and post resynchronization therapy evaluated by 123I-MIBG myocardial scintigraphy. J Nucl Cardiol. 2007; 14(6):852-9. DOI: 10.1016/j.nuclcard.2007.08.004. View

13.

Matsui H, Udaka F, Oda M, Tamura A, Kubori T, Nishinaka K . Metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease also decreases at thyroid. Ann Nucl Med. 2005; 19(3):225-9. DOI: 10.1007/BF02984609. View

14.

Jacobson A, Senior R, Cerqueira M, Wong N, Thomas G, Lopez V . Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55(20):2212-21. DOI: 10.1016/j.jacc.2010.01.014. View

15.

Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R . Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008; 49(2):225-33. DOI: 10.2967/jnumed.107.042564. View

16.

Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schafers M . Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010; 37(9):1802-12. DOI: 10.1007/s00259-010-1491-4. View

17.

Nishisato K, Hashimoto A, Nakata T, Doi T, Yamamoto H, Nagahara D . Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: quantification of cardiac tracers in patients with ICDs. J Nucl Med. 2010; 51(8):1241-9. DOI: 10.2967/jnumed.110.074971. View

18.

Melander A, Ljunggren J, NORBERG K, Persson B, ROSENGREN E, Sundler F . Sympathetic innervation and noradrenaline content of normal human thyroid tissue from fetal, young, and elderly subjects. J Endocrinol Invest. 1978; 1(2):175-7. DOI: 10.1007/BF03350368. View

19.

Friedman N, Hassan A, Grady E, Matsuoka D, Jacobson A . Efficacy of thyroid blockade on thyroid radioiodine uptake in 123I-mIBG imaging. J Nucl Med. 2014; 55(2):211-5. DOI: 10.2967/jnumed.113.124826. View

20.

Vallabhajosula S, Nikolopoulou A . Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology. Semin Nucl Med. 2011; 41(5):324-33. DOI: 10.1053/j.semnuclmed.2011.05.003. View